구조모아 (StructureMoa)항암 chemical structure spider web
방문타깃 · 모달리티 · 임상 근거 · 비임상 맥락으로 최대 5개 프로그램을 나란히 비교합니다. · 다음 갱신 D-6 · 마지막 9월 2일
현재 선택: 1개 · 임상 갱신 필요 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | Genetical Recombination (Brentuximab Vedotin, Brentuximab Vedotin (Genetical Recombination)) Seagen / Takeda·Peripheral T Cell Lymphoma 93 trials |
|---|---|
Overview Program | Brentuximab Vedotin (Genetical Recombination) |
Overview Company | Seagen / Takeda |
Overview Modality | ADC |
Overview Target | Peripheral T Cell Lymphoma |
Overview Indication | Untreated CD30-Positive Hodgkin's Lymphoma |
Overview Phase | PRECLINICAL |
Overview Status | ACTIVE |
Overview Content status | Standard Database |
Overview Data Confidence | Data Confidence · Medium |
Overview Development Signal | Development Signal · Watch |
Overview Approval status | Investigational |
Technology Payload | vedotin and the anti-HER2 trastuzumab deruxteca |
Technology Linker | linker, or payload that have limited their development |
MoA Mechanism | targeting specific cell surface antigens, many ADCs have also been associated with unique toxicities related to the antigen |
MoA Biomarker | biomarkers for HBsAg clearance and responses to Peg-IFN-α in HBeAg-negative chronic hepatitis B patient |
PK/PD Species | Mouse |
PK/PD Animal (cat.) | Mouse, In vitro |
PK/PD Experiment | pd |
Toxicology Species | Mouse |
Toxicology Animal (cat.) | Mouse |
Toxicology Major finding | Effectiveness and safety of brentuximab vedotin-containing regimen versus standard chemotherapy in relapsed or refractory Hodgkin lymphoma: a multicenter cohort study.. Hodgkin lymphoma (HL) constitutes 3.4% of all cancers in Saudi Arabia, with advanced-stage relapse rates reaching 40%. While the anti-CD30 agent brentuximab vedotin (BV) has established efficacy, local data are limited. This study … |
Clinical Safety signal | Effectiveness and safety of brentuximab vedotin-containing regimen versus standard chemotherapy in relapsed or refractory Hodgkin lymphoma: a multicenter cohort study.. Hodgkin lymphoma (HL) constitutes 3.4% of all cancers in Saudi Arabia, with advanced-stage relapse rates reaching 40%. While the anti-CD30 agent brentuximab vedotin (BV) has established efficacy, local data are limited. This study … |
Clinical Selected reported efficacy | ORR 89.5% |
Clinical Reported ORR | 89.5% |
Clinical Result source | ClinicalTrials.gov NCT02588651 |
Clinical Program phase | PRECLINICAL |
Clinical Trial activity | No active/completed counts |
Clinical Trial ref | NCT02588651 |
타깃 · 모달리티 · 임상 근거 · 비임상 맥락으로 최대 5개 프로그램을 나란히 비교합니다. · 다음 갱신 D-6 · 마지막 9월 2일
현재 선택: 1개 · 임상 갱신 필요 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | Genetical Recombination (Brentuximab Vedotin, Brentuximab Vedotin (Genetical Recombination)) Seagen / Takeda·Peripheral T Cell Lymphoma 93 trials |
|---|---|
Overview Program | Brentuximab Vedotin (Genetical Recombination) |
Overview Company | Seagen / Takeda |
Overview Modality | ADC |
Overview Target | Peripheral T Cell Lymphoma |
Overview Indication | Untreated CD30-Positive Hodgkin's Lymphoma |
Overview Phase | PRECLINICAL |
Overview Status | ACTIVE |
Overview Content status | Standard Database |
Overview Data Confidence | Data Confidence · Medium |
Overview Development Signal | Development Signal · Watch |
Overview Approval status | Investigational |
Technology Payload | vedotin and the anti-HER2 trastuzumab deruxteca |
Technology Linker | linker, or payload that have limited their development |
MoA Mechanism | targeting specific cell surface antigens, many ADCs have also been associated with unique toxicities related to the antigen |
MoA Biomarker | biomarkers for HBsAg clearance and responses to Peg-IFN-α in HBeAg-negative chronic hepatitis B patient |
PK/PD Species | Mouse |
PK/PD Animal (cat.) | Mouse, In vitro |
PK/PD Experiment | pd |
Toxicology Species | Mouse |
Toxicology Animal (cat.) | Mouse |
Toxicology Major finding | Effectiveness and safety of brentuximab vedotin-containing regimen versus standard chemotherapy in relapsed or refractory Hodgkin lymphoma: a multicenter cohort study.. Hodgkin lymphoma (HL) constitutes 3.4% of all cancers in Saudi Arabia, with advanced-stage relapse rates reaching 40%. While the anti-CD30 agent brentuximab vedotin (BV) has established efficacy, local data are limited. This study … |
Clinical Safety signal | Effectiveness and safety of brentuximab vedotin-containing regimen versus standard chemotherapy in relapsed or refractory Hodgkin lymphoma: a multicenter cohort study.. Hodgkin lymphoma (HL) constitutes 3.4% of all cancers in Saudi Arabia, with advanced-stage relapse rates reaching 40%. While the anti-CD30 agent brentuximab vedotin (BV) has established efficacy, local data are limited. This study … |
Clinical Selected reported efficacy | ORR 89.5% |
Clinical Reported ORR | 89.5% |
Clinical Result source | ClinicalTrials.gov NCT02588651 |
Clinical Program phase | PRECLINICAL |
Clinical Trial activity | No active/completed counts |
Clinical Trial ref | NCT02588651 |
추천 비교
추천 비교